Newbridge Financial Services Group Inc. Purchases 4,457 Shares of Johnson & Johnson $JNJ

Key Points

• Newbridge Financial boosted its stake in Johnson & Johnson by 191.5%, buying 4,457 shares to hold 6,784 shares worth about $1.404 million at quarter-end.
• Analyst sentiment is broadly positive with multiple price-target raises and a consensus "Moderate Buy" (average PT $237.57), while a recent CE‑marked launch of the VARIPULSE Pro pulse‑field ablation system provides a potential MedTech growth catalyst.
• Johnson & Johnson reported $2.46 EPS and $24.28 billion in revenue for the quarter, with institutional ownership at 69.55% and insiders selling roughly 30,142 shares (~$7.36M) over the past three months.

Newbridge Financial Services Group Inc. boosted its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 191.5% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,784 shares of the company's stock after purchasing an additional 4,457 shares during the period. Newbridge Financial Services Group Inc.'s holdings in Johnson & Johnson were worth $1,404,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Abich Financial Wealth Management LLC bought a new position in Johnson & Johnson during the 3rd quarter valued at about $26,000. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson during the 2nd quarter valued at about $27,000. Clayton Financial Group LLC bought a new position in Johnson & Johnson in the 3rd quarter valued at $28,000. Semmax Financial Advisors Inc. raised its position in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. Finally, Turning Point Benefit Group Inc. bought a new position in Johnson & Johnson in the 3rd quarter valued at $41,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: TD Cowen reiterated a Buy and set a $250 price target, underpinning near-term upside expectations from improving fundamentals and pipeline momentum. TD Cowen Buy, $250 PT
• Positive Sentiment: Citi and other brokers have raised price targets and highlighted J&J’s stronger MedTech outlook, supporting bullish analyst sentiment that could prop the shares if Q1 confirms recovery. Citigroup Forecasts Strong Price Appreciation for JNJ
• Positive Sentiment: J&J launched the VARIPULSE Pro pulsed field ablation system in Europe (CE mark), adding a potential growth driver for its MedTech segment as real‑world studies and conference data are collected. This rollout is a concrete revenue catalyst if adoption scales. Johnson & Johnson PFA Launch Puts VARIPULSE Pro And Valuation In Focus
• Neutral Sentiment: Coverage pieces in Barron’s and TipRanks emphasize the rebound narrative heading into earnings, raising visibility but not adding new fundamental proof — they may support sentiment but won’t move the stock without data. Buy Johnson & Johnson Ahead of Earnings
• Neutral Sentiment: Market / media mentions (lists, S&P visibility) and multiple analyst notes increase attention; these can amplify moves but are secondary to earnings and device adoption. JNJ Gains Visibility As S&P 500 Trends Shift
• Negative Sentiment: Zacks warns that rising biosimilar competition and pricing pressure remain material headwinds for J&J’s pharma business; those risks mean the upcoming Q1 print could produce downside if guidance or growth details disappoint. Should You Buy, Sell or Hold JNJ Ahead of Q1
• Negative Sentiment: Upcoming Q1 estimates and metric expectations introduce short‑term volatility: if reported drug growth or MedTech momentum falls short of elevated analyst hopes, the stock could underperform. Wall Street Estimates for JNJ Q1

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on JNJ shares. Wolfe Research lifted their price objective on Johnson & Johnson from $225.00 to $240.00 and gave the company an "outperform" rating in a research report on Monday, January 5th. Leerink Partners lifted their price objective on Johnson & Johnson from $201.00 to $232.00 and gave the company a "market perform" rating in a research report on Thursday, January 22nd. Stifel Nicolaus lifted their price objective on Johnson & Johnson from $205.00 to $220.00 and gave the company a "hold" rating in a research report on Thursday, January 22nd. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Saturday, February 14th. Finally, Rothschild & Co Redburn boosted their target price on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a "neutral" rating in a research note on Thursday, February 19th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $237.57.

Johnson & Johnson Trading Down 0.1%

JNJ stock opened at $241.13 on Friday. The company has a market cap of $580.78 billion, a P/E ratio of 21.82, a PEG ratio of 2.39 and a beta of 0.34. Johnson & Johnson has a twelve month low of $145.13 and a twelve month high of $251.71. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The business has a fifty day moving average of $241.07 and a 200-day moving average of $214.54.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 1,322 shares of the business's stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.